Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | LPL | P06858 | 8/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297920 | 1.00 | FFAR1 (0.58) | FFAR1LPLLIPGPDK2GBA1 | |
| SCHEMBL9281960 | 0.99 | FFAR1 (0.59) | FFAR1LPLLIPGPDK2GBA1 | |
| SCHEMBL1854359 | 0.94 | FFAR1 (0.61) | FFAR1LPLLIPGPDK2JAK2 | |
| SCHEMBL20759 | 0.88 | FFAR1 (0.64) | FFAR1LPLLIPGPDK2JAK2 | |
| SCHEMBL22748460 | 0.87 | FFAR1 (0.56) | FFAR1LPLLIPGGBA1 | |
| SCHEMBL23812347 | 0.87 | FFAR1 (0.56) | FFAR1LPLLIPGGBA1 | |
| SCHEMBL25248244 | 0.84 | FFAR1 (0.53) | FFAR1LIPGPDK2JAK2 | |
| SCHEMBL17247560 | 0.84 | FFAR1 (0.58) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL28398484 | 0.82 | FFAR1 (0.57) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL29582665 | 0.82 | FFAR1 (0.61) | FFAR1LPLLIPGF11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 1395/4885LPL 1442/4885LIPG 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.